A Phase II, Randomized, Double-Blind, Placebo-Controlled Study for High-Dose Hydroxocobalamin (Vitamin B12A) for Vasopressor Refractory Hypotension Following Cardiopulmonary Bypass
Phase: PHASE2
Conditions: Vasoplegic Syndrome
Sponsor: Mayo Clinic

 
 
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY FOR HIGH-DOSE 
HYDROXOCOBALAMIN (VITAMIN B12A) FOR 
VASOPRESSOR REFRACTORY HYPOTENSION FOLLOWING 
CARDIOPULMONARY BYPASS 
 
NCT03735316 
 
 
03NOV2021 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 1 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY FOR HIGH-DOSE 
HYDROXOCOBALAMIN (VITAMIN B12A) FOR VASOPRESSOR 
REFRACTORY HYPOTENSION FOLLOWING 
CARDIOPULMONARY BYPASS 
 
 
 
Study Product: 
Hydroxocobalamin (Vitamin B12a), marketed as Cyanokit® 
Protocol Number: (IRBe) 
17-011130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Version 9: 
3Nov2021 
 
 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 2 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
Table of Contents 
 
STUDY SUMMARY ...................................................................................................................................... 5 
1 
INTRODUCTION ................................................................................................................................. 6 
1.1 
BACKGROUND .................................................................................................................................... 6 
1.2 
INVESTIGATIONAL AGENT .................................................................................................................... 8 
1.3 
PRECLINICAL DATA ............................................................................................................................. 8 
1.4 
CLINICAL DATA TO DATE..................................................................................................................... 9 
1.5 
DOSE RATIONALE................................................................................................................................ 9 
1.6 
RISKS AND BENEFITS ........................................................................................................................... 9 
2 
STUDY OBJECTIVES ........................................................................................................................ 10 
3 
STUDY DESIGN ................................................................................................................................. 10 
3.1 
GENERAL DESCRIPTION ..................................................................................................................... 11 
3.2 
NUMBER OF SUBJECTS ....................................................................................................................... 11 
3.3 
DURATION OF PARTICIPATION ............................................................................................................ 11 
3.4 
PRIMARY STUDY ENDPOINTS .............................................................................................................. 12 
3.5 
SECONDARY STUDY ENDPOINTS ......................................................................................................... 12 
3.6 
PRIMARY SAFETY ENDPOINTS ............................................................................................................ 13 
3.7 
IDENTIFICATION OF SOURCE DATA ...................................................................................................... 13 
4 
SUBJECT SELECTION ENROLLMENT AND WITHDRAWAL ...................................................... 15 
4.1 
INCLUSION CRITERIA ......................................................................................................................... 15 
4.2 
EXCLUSION CRITERIA ........................................................................................................................ 16 
4.3 
SUBJECT RECRUITMENT, ENROLLMENT AND SCREENING ....................................................................... 16 
4.4 
EARLY WITHDRAWAL OF SUBJECTS .................................................................................................... 16 
4.4.1 
When and How to Withdraw Subjects ........................................................................................ 16 
4.4.2 
Data Collection and Follow-up for Withdrawn Subjects .............................................................. 16 
5 
STUDY DRUG .................................................................................................................................... 16 
5.1 
DESCRIPTION .................................................................................................................................... 16 
5.2 
TREATMENT REGIMEN ....................................................................................................................... 17 
5.3 
METHOD FOR ASSIGNING SUBJECTS TO TREATMENT GROUPS ................................................................ 17 
5.4 
PREPARATION AND ADMINISTRATION OF STUDY DRUG ......................................................................... 17 
5.5 
SUBJECT COMPLIANCE MONITORING ................................................................................................... 17 
5.6 
PRIOR AND CONCOMITANT THERAPY .................................................................................................. 17 
5.7 
PACKAGING ...................................................................................................................................... 17 
5.7.1 
Return or Destruction of Study Drug ......................................................................................... 17 
6 
STUDY PROCEDURES ...................................................................................................................... 18 
6.1 
VISIT 1 ............................................................................................................................................. 17 
7 
STATISTICAL PLAN ......................................................................................................................... 19 
7.1 
SAMPLE SIZE DETERMINATION ........................................................................................................... 19 
7.2 
STATISTICAL METHODS ..................................................................................................................... 19 
7.3 
SUBJECT POPULATION(S) FOR ANALYSIS ............................................................................................. 20 
8 
SAFETY AND ADVERSE EVENTS ................................................................................................... 20 
8.1 
DEFINITIONS ..................................................................................................................................... 21 
8.2 
RECORDING OF ADVERSE EVENTS ....................................................................................................... 23 
8.3 
REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS .......................................... 23 
8.3.1 
Sponsor-Investigator reporting: notifying the Mayo IRB ............................................................. 23 
8.3.2 
Sponsor-Investigator reporting: Notifying the FDA ..................................................................... 22 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 3 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
8.4 
UNMASKING/UNBLINDING PROCEDURES ............................................................................................. 25 
8.5 
STOPPING RULES ............................................................................................................................... 25 
8.6 
MEDICAL MONITORING ..................................................................................................................... 25 
8.6.1 
Internal Data and Safety Monitoring Board ............................................................................... 25 
8.6.2 
Independent Data and Safety Monitoring Board ......................................................................... 25 
9 
DATA HANDLING AND RECORD KEEPING .................................................................................. 25 
9.1 
CONFIDENTIALITY ............................................................................................................................. 25 
9.2 
SOURCE DOCUMENTS ........................................................................................................................ 26 
9.3 
CASE REPORT FORMS ........................................................................................................................ 26 
9.4 
RECORDS RETENTION ........................................................................................................................ 26 
10 
STUDY MONITORING, AUDITING, AND INSPECTING ................................................................ 27 
10.1 
STUDY MONITORING PLAN ............................................................................................................ 27 
10.2 
AUDITING AND INSPECTING ........................................................................................................... 27 
11 
ETHICAL CONSIDERATIONS ......................................................................................................... 27 
12 
STUDY FINANCES ............................................................................................................................ 28 
12.1 
FUNDING SOURCE ......................................................................................................................... 28 
12.2 
CONFLICT OF INTEREST ................................................................................................................. 28 
13 
PUBLICATION PLAN ....................................................................................................................... 28 
14 
REFERENCES ................................................................................................................................... 28 
15 
ATTACHMENTS ............................................................................................................................... 30 
 
 
 
 
 
 
 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 4 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
 
List of Abbreviations 
 
 
LIST OF ABBREVIATIONS 
AE 
Adverse Event/Adverse Experience 
CFR 
Code of Federal Regulations 
CRF 
Case Report Form 
DSMB 
Data and Safety Monitoring Board 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
HIPAA 
Health Insurance Portability and Accountability Act 
IB 
Investigator’s Brochure 
 
 
IND 
Investigational New Drug Application 
IRB 
Institutional Review Board 
LOS 
PHI 
 
Length of Stay 
Protected Health Information 
PI 
Principal Investigator 
SAE 
Serious Adverse Event/Serious Adverse Experience 
SOP 
Standard Operating Procedure 
 
 
 
 
 
 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 5 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
Study Summary 
Title 
A phase II, randomized, double-blind, placebo-controlled study for 
High-dose Hydroxocobalamin (Vitamin B12a) for Vasopressor 
Refractory Hypotension Following Cardiopulmonary Bypass 
Running Title 
Vitamin B12a Vasoplegic Syndrome 
Protocol Number 
17-011130 
Phase 
Clinical study phase II 
Methodology 
Study design type: double blind; Randomized, placebo 
Overall Study 
Duration 
2 years 
Subject Participation 
Duration 
30 days 
Single or Multi-Site  
Single 
Objectives 
To demonstrate an improvement in arterial blood pressure and a 
decrease in vasopressor requirement with administration of B12a in 
patients with post-cardiotomy vasoplegic syndrome on high-dose 
vasopressors. 
Number of Subjects 
50 
Diagnosis and Main 
Inclusion Criteria 
Vasoplegic syndrome – inclusion criteria are patients with vasoplegic 
syndrome as defined below who are also on high-dose vasopressors.  
Study Product, Dose, 
Route, Regimen 
Hydroxocobalamin marketed as Cyanokit®, 5g, IV, Infused once over 
15 min. Unblinded dose of Cyanokit® can be ordered within the first 4 
hours at the discretion of the primary care team.  
Duration of 
Administration 
Infuse drug over 15 minute period. 
Reference therapy 
Placebo 
Statistical 
Methodology 
 
 
 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 6 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
1 Introduction 
 
 
This document is a protocol for a human research study. This study will be carried out in 
accordance with the applicable United States government regulations and Mayo Clinic research 
policies and procedures.  
 
The primary aim of this study is to demonstrate an improvement in mean arterial blood pressure 
over the first 4 hours after administration of B12a as a 5g infusion.  Secondary aims include 
evaluation for a decrease in vasopressor requirement in patients with post-cardiotomy vasoplegic 
syndrome on high-dose vasopressors after administration of B12a as a 5g infusion over the first 4 
hour.  Additional secondary aims include assessment of the effect of B12a on other important 
clinical endpoints and to potentially assist in power analysis and study design in larger future 
clinical trials.  These endpoints include indices of perfusion such as lactate, and serum acid base 
balance, time to discharge from the ICU, multi-organ dysfunction, need for mechanical 
circulatory support, coagulopathy and transfusion requirements as well as mortality. 
 
Significance:  
 
VS is a common complication after cardiopulmonary bypass (CPB), occurring in up to 8-12% of 
cases[1-4].  It remains a clinical diagnosis with a significant burden of disease.  One series 
reports a mortality of 24% and another at 25% in patients with prolonged catecholamine 
refractory VS[5, 6].  In addition prolonged intensive care unit (ICU) and hospital stays as well as 
the risks associated with increased catecholamine administration result in further increased 
morbidity.  Calculating the economic costs associated with prolonged ICU stays has inherent 
limitations, however, 2015 unadjusted estimates of the cost of ICU stays were approximately 
$4500/day and as high as $10,794/day in mechanically ventilated patients[7, 8].  Although these 
costs decline with increasing days in the ICU they may be higher in the often more complex 
cardiac surgical population [9].  Therefore finding therapies that decrease the need for 
vasopressor support and ideally decrease ICU stays as well as mortality is of substantial 
significance. 
 
Innovation:  
 
Nitric oxide and it’s downstream effects likely play a central role in the pathophysiology of 
VS[1].  Hydroxocobalamin (B12a) an inhibitor of nitric oxide and guanylate cyclase is emerging 
as potential therapeutic target[10, 11].  This has been demonstrated through its use in several 
case reports in both cardiac surgery and during liver transplantation[2, 12].  At our institution a 
series submitted for publication of 24 patients showed a significant improvement in blood 
pressure and decrease in vasopressor requirement after B12a administration in patients with VS 
after cardiac surgery. 
 
 
1.1 
Background 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 7 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
 
i) Introduction and Feasibility 
 
Hypotension that fails to respond to the current armamentarium of vasopressors is a common 
complication after cardiopulmonary bypass (CPB), occurring in 8-12% of cases[1, 2, 4].  
Commonly labeled “vasoplegic syndrome” (VS), although no universally accepted formal 
definition exists, it is generally defined as hypotension occurring as a result of low systemic 
vascular resistance (SVR) in the setting of normal to high cardiac output (CO), and euvolemia.  
Subsequent hypoperfusion can lead to end organ damage and in prolonged catecholamine 
refractory VS mortality approaches 25% [5, 6]. 
 
Routine treatment of vasodilatory hypotension after CPB has mirrored treatment of vasodilatory 
shock in other inflammatory contexts like sepsis and anaphylaxis.  Hemodynamics are supported 
through both volume optimization as well vasopressors and inotropes.  Catecholamines continue 
to be the most widely used agents with epinephrine, norepinephrine, phenylephrine and 
dobutamine being available choices.  Vasopressin is also commonly used with the 
pathophysiological basis for its use in these patients being vasopressin deficiency which is 
believed to contribute to VS.  Corticosteroids are another option in patients believed to be steroid 
deficient and the recent ATHOS-3 trial highlights the possibility of angiotensin II being a 
therapeutic agent in these patients.[13] 
 
As described above, treatment for the most part has been directed at the physiological 
consequences of the syndrome with less emphasis on addressing the underlying pathology. The 
pathogenesis of VS is multifactorial and not fully understood and has been discussed in previous 
reviews [1, 6, 14].  Upregulation of inducible nitric oxide synthase (iNOS) is believed to play an 
important role and has been a target for therapeutic intervention through the use of methylene 
blue for more than 20 years, particularly in cases refractory to catecholamine administration[15].  
Nitric oxide (NO) is involved in basal vasomotor tone through its activation of guanylyl cyclase 
and cGMP.  In addition to its action in the regulation of small resistance arterioles and therefore 
systemic blood pressure it also plays a role in pulmonary vascular resistance (PVR) as well 
autoregulation of important vascular beds including in the heart, the brain and the kidneys [16].  
Beyond its role as a vasodilator there is evidence suggesting NO contributes to a decrease in 
cellular responsiveness to catecholamines[16].   
 
Given these factors it’s possible that treatment at the level of the underlying pathological 
process, inhibition of iNOS and its downstream pathways, leads to a higher achievable target 
blood pressure as catecholamines become more effective on top of the underlying improvement 
in blood pressure achieved through NO removal alone.  Additionally some of the adverse effects 
seen as catecholamine doses increase including arrhythmias, as well as malperfusion through 
important vascular beds and subsequent adverse physiological sequelae may be attenuated [17].   
 
The concept of treating post-cardiotomy VS at the level of its pathological root led to the use of 
Methylene Blue (MB) in the 1990s. The first series of six patients was reported in 1996 and was 
followed with a number of case reports and series over the following decade [17-20].   
 
MB was initially used as a rescue medication in cases of catecholamine refractory VS with 
hesitation about its use as first line therapy.  Two randomized controlled trials then pointed to 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 8 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
benefit both with prophylactic use and as early therapy post-CPB prior to the development of 
catecholamine refractory VS. Ozal et al. showed benefit with use of MB as a preventative 
therapy in patients at high risk of VS[21] and Levin and colleagues reported benefit with the 
early use of MB in patients with VS post-CPB[5].   
 
In spite of these benefits there are several reasons to be cautious when using MB as therapy in 
post-CPB VS.  Firstly, given there is no clear definition of VS, it isn’t clear which patients are 
truly vasoplegic and therefore may benefit from its use.  On top of this a physiological diagnosis 
by no means guarantees the underlying process is NO and cGMP mediated and therefore a 
diagnosis of VS alone may not predict response definitively. In addition it remains unclear when 
MB should be administered in relation to the onset of VS.  It has been proposed that there may 
be windows of opportunity for treatment of VS with the first 8 hours being possibly the ideal 
time to intervene [15, 22].  On top of this, a retrospective review published in 2013 showed an 
independent association between MB administration and mortality [23]. These uncertainties 
coupled with several potentially serious adverse effects have led several authors to conclude MB 
is better confined to use as a rescue medication and should be avoided in certain populations[23-
25].   
MB inhibits monoamine oxidase A (MAO-A) resulting in prolonged action of serotonin, 
norepinephrine and epinephrine.  Although this can help augment blood pressure the inhibition 
of MAO-A can lead to serotonin syndrome when MB is combined with other agents that also 
increase serotonin, such as fentanyl and SSRIs[26].  Other unfavorable effects of MB include 
increasing pulmonary vascular resistance (PVR), decrease in mesenteric and renal blood flow, 
cardiac arrhythmias and worsening gas exchange[4, 21, 25].  In large doses it has also been 
associated with hemolytic anemia and hyperbilirubinemia [27]. 
 
1.2 
Investigational Agent 
 
Hydroxocobalamin marketed as Cyanokit®, 5g, IV, Infused once over 15 min. Unblinded dose 
of Cyanokit® can be ordered within the first 4 hours at the discretion of the primary care team. 
The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be 
reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.  It appears as a dark red 
solution after reconstitution.  
1.3 
Preclinical Data 
 
ii) Preliminary Studies 
 
Concerns over the host of adverse effects seen with the use of MB have led to a search for other 
NOS inhibitors.  One such medication is hydroxocobalamin also known as vitamin B12a (B12a).  
B12a has been used in Europe for the treatment of cyanide toxicity for over 40 years with an 
excellent safety profile[28].  Hypertension is one of the possible effects of B12a likely through 
inhibition of both NOS and cGMP [2, 10].  Given its lack of MOA-A inhibition it does not result 
in serotonin syndrome.  Several case reports have demonstrated its effectiveness in patients with 
vasoplegia with one suggesting it reduced the risks of vasospasm associated with high dose 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 9 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
catecholamine administration and another hypothesizing a synergistic effect when used with MB 
[2, 12, 29].   
 
1.4 
Clinical Data to Date 
 
To date no prospective studies have looked at the use of B12a in this population.  Currently it is 
FDA approved for use in cyanide toxicity with a more extensive body of literature for that 
indication[30].   
 
At our institution a protocol was put in place for the use of B12a in patients with refractory VS 
after cardiac surgery.  A retrospective review of the data sent for publication found a statistically 
significant increase in blood pressure and decrease in vasopressor requirement in 24 patients who 
received B12a in post-cardiotomy VS.  This included both patients who had not received MB 
and patients who were B12a non-responders.  
 
In addition a case series was recently published in the Canadian Journal of Anesthesiology also 
showing a favorable response in a subset of patients with post-cardiotomy VS receiving B12a 
[31]. 
1.5 
Dose Rationale  
 
The selected dose is the current FDA approved dose for use in cyanide toxicity.  In our review of 
the data of patients with VS receiving B12a this has been associated with a significant change in 
blood pressure.  The protocol requires the full dose of 5g to avoid the heterogeneity of 
intervention that might occur if partial doses were given.  In order to avoid blood pressure 
overshoot, which has been described in this population, the protocol allows for titration of 
vasopressors  while the B12a is infusing, to maintain the desired maximum blood pressure [31]. 
 
The drug is sold for intravenous administration and this is the most practical route given the 
patient population.  
 
1.6 
Risks and Benefits 
 
The potential risks include mishandling of patient information, anaphylaxis and transient skin 
discoloration due to study drug administration, as yet unknown adverse effects of the study drug, 
the potential that placebo is inferior to the study drug and therefore patients receiving placebo are 
adversely affected through omission.  Plasma discoloration has also been shown to interfere with 
intermittent hemodialysis in which case there is the potential for need for continuous renal 
replacement therapy (CRRT) use instead.  CRRT has been used uneventfully for this reason in 
the past [32]. These risks are mostly low or transient in nature and for most people are 
outweighed by the benefits which include.   
 
Direct benefit from receiving the study drug, increased vigilance in regards to hemodynamic 
monitoring, and a large potential scientific yield given the magnitude of this problem both in 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 10 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
terms of the frequency with which it occurs and the high rate of morbidity and mortality 
associated.  Anecdotal findings and retrospective review of case series point to this being a 
promising therapeutic option however prospective trials like this one are needed to more strongly 
support its use.  For patients that have no response to the administration of study drug or placebo 
standard of care will be followed. Patients in this scenario would not be at a disadvantage to what 
they would have otherwise received.   Rescue with methylene blue will also be an option in 
circumstances where it is considered potentially useful. 
2 Study Objectives 
 
Primary Objective 
1. Change in Mean Arterial Pressure – To assess the efficacy during the first 4 hours 
after B12a administration on increasing mean arterial pressure in patients with 
vasoplegic syndrome on high-dose vasopressors as defined by a norepinephrine 
equivalent of 0.1mcg/kg/min. 
 
Secondary Objective 
 
1. Change in vasopressor infusion rates. (first 4 hours) 
2. Change in Systolic Blood Pressure (first 4 hours) 
3. Thirty day mortality 
4. Hospital length of stay (LOS) 
5. ICU LOS 
6. Ventilator time (hrs) 
7. Urine output 
8. Total crystalloid and albumin administration (first 48 hrs) 
9. End organ dysfunction during the first seven days will not be directly collected in the 
CRF but will be captured retrospectively in supportive documentation: (Stroke, AKI, 
Liver enzyme elevation, lactate, renal replacement therapy) 
10. Maximum SOFA score (First 7 days) 
11. New arrhythmias (First 7 days) 
12. Need for Rescue with MB  
13. Need for mechanical circulatory support 
14. Change in INR, platelet count, fibrinogen 
15. Need for transfusion of allogeneic packed red blood cells, plasma, platelets and 
fibrinogen.  
 
 
 
 
 
 
3 Study Design 
 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 11 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
3.1 
General Description 
This will be a phase I/II, single-center, double-blind, placebo-controlled, randomized, intent-to-
treat study among a placebo group and a group receiving B12a for clinically diagnosed VS after 
CPB.  Subjects will be screened on the medical record and consented in the preoperative area or 
patient/family will be approached for consent if they are close to qualifying for the study after 
the surgical procedure. If consent is given they will be enrolled and monitored after 
cardiopulmonary bypass for cardiac surgery for inclusion criteria as defined in table 1.  B12a will 
be administered as an infusion of 5g for the first dose and must be reconstituted to a 25mg/mL 
concentration.  The initial 5g dose will be given over a period of 15 min. If there is a non-
sustained response after the first dose a second dose may be administered within the first 4 hours 
at the discretion of the primary care team. This strategy is consistent with current FDA approved 
dosages. If there is no response, rescue with methylene blue will be at the discretion of the 
primary anesthesiologist or intensivist and will be measured as an outcome.  Patients/Legal 
Authorized Representative (LAR) will be consented on the basis of 1 through 4 and randomized 
for inclusion based on 5 in the table below.  Exclusion criteria are also included table 1.  After 
randomization and drug administration initial vital signs and hemodynamic measurements will 
be taken.  The electronic medical record will then be used to collect patient data retrospectively.  
Patients will receive 1 follow up phone call at 1 month after enrollment. 
 
 
3.2 
Number of Subjects 
 
1000 to 2000 subjects will be enrolled in order to accrue a total of 50 subjects.  
 
3.3 
Duration of Participation 
 
Patients will be randomized and administered study drug if criteria are met within the first 24hrs 
after being removed from cardiopulmonary bypass.  Once study drug is given, hemodynamic 
variables will be monitored the first 30 minutes, all adverse events will be monitored the first 12 
hours and development of acute kidney injury (AKI) and stroke will be monitored for 72 hours. 
Data will be collected the first 7 days through the electronic medical record and at 30 days the 
patient will be called for follow up and assessment of 30 day mortality.  
 
 
 
 
 
 
 
 
 
 
 
 
Screening/Consent 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 12 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 
Primary Study Aims 
 
Change in Mean Arterial Pressure over the first 4 hours post B12a administration 
3.5 
Secondary Study Aims 
 
1. 
Change in vasopressor infusion rates. (first 4 hours) 
2. 
Change in Systolic Blood Pressure (first 4 hours) 
3. 
Thirty day mortality 
Randomization 
Treatment Group 1 
B12a 
Treatment Group 2 
Placebo 
Hospital Course with 
Data Collection  
Follow-up Phone Call at 
30 Days 
Data Review and 
Analysis Projected to be 
at 2 years 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 13 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
4. 
Hospital length of stay (LOS) 
5. 
ICU LOS 
6. 
Ventilator time (hrs) 
7. 
Urine output (Daily for 7 days) 
8. 
Total crystalloid and albumin administration (amount given over first 48 hrs) 
9. 
End organ dysfunction during the first seven days will not be directly collected in the 
CRF but will be captured retrospectively in supportive documentation: (Stroke, AKI 
(AKIN criteria), Liver enzyme elevation, lactate, renal replacement therapy all daily for 
first seven days) 
10. 
Maximum SOFA score (daily for first 7 days) 
11. 
New arrhythmias (daily for first 7 days) 
12. 
Need for Rescue with MB  
13. 
Need for mechanical circulatory support 
14. 
Change in INR, platelet count, fibrinogen (daily for first 7 days) 
15. 
Need for transfusion of allogeneic packed red blood cells, plasma, platelets and 
fibrinogen. (Units and L transfused over first 48 hrs) 
16.  
Compare vitamin B12 assay and heavy metal quant in patients who receive study drug 
 
3.6 
Primary Safety Aims 
 
Primary safety endpoints will include evaluation for development of anaphylaxis, blood pressure 
overshoot as defined by a systolic blood pressure above 140mmHg during the first 4 hours of 
administration, as well as the following. 
1. Thirty day mortality 
2. Hospital length of stay (LOS) 
3. ICU LOS 
4. Ventilator time in hours 
5. End organ dysfunction during the 1st seven days will not be directly collected in the 
CRF but will be captured retrospectively in supportive documentation:  
i. Stroke (CT or MRI confirmed hemorrhagic or ischemic 
ii. AKI as defined by AKIN criteria 
6. SOFA score 
7. New arrhythmias 
8. Need for mechanical circulatory support 
9. Statistically significant change in INR, platelet count, fibrinogen 
10. Need for transfusion of allogeneic packed red blood cells, plasma, platelets and 
fibrinogen.  
 
 
3.7 
Identification of Source Data 
 
The following source data will be directly recorded on the Case Report Form (CRF):  
• Vital signs (T0+30 min, T0 represents time of drug administration) 
o Cardiac index  

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 14 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
o MAP  
o SBP  
o Systolic Pulmonary Blood Pressure  
o Right Atrial Pressure  
 
• Vasopressor infusion rates (T0+30 min, T0 represents time of drug administration) 
o Norepinephrine mcg/kg/min  
o Epinephrine mcg/kg/min  
o Vasopressin unit/min  
o Calcium mg/hour  
o Dopamine mcg/kg/min  
 
The following source data will be directly collected in the Case Report Form (CRF),  if we are 
not able to capture the data in the CRF due to limitations, it will be captured retrospectively in 
supportive documentation (study source documents, EMR): 
• Laboratory tests will be taken as is standard in this patient population with no added tests 
specific for the study.  Results and clinical interpretation with be via the EMR 
o Creatinine, ABG (FiO2, PaO2, PaCO2, pH, Bicarb, Base Deficit, methemoglobin 
percentage), Lactate, INR, PTT, AST, ALT, Bilirubin,  Hemoglobin, platelets 
• Vitamin B12 assay and heavy metal quant results 24 hours and 72 hours after drug 
administration 
• Urine output at each 24 hours.  
• Vital signs 
• Cardiac index at 15 min intervals from administration time T45 through the first 4 hours 
if the participant has a continuous pulmonary artery catheter. Cardiac index 30 minutes 
after administration time, times two, followed by every hour for 4 hours if the patient has 
a non-continuous pulmonary artery catheter and based upon the availability of the 
technician/therapist.  
• MAP at 15 min intervals from administration time T45 through the first 4 hours 
• SBP at 15 min intervals from administration time T45 through the first 4 hours 
• Systolic Pulmonary Blood Pressure at 15 min intervals from administration time T45 
through the first 4 hours 
• Right Atrial Pressure at 15 min intervals from administration time T45 through the first 4 
hours 
• Hospital length of stay (LOS) (Days) 
• ICU LOS (Days) 
• Ventilator time (Hours) 
• End organ dysfunction during the first seven days will not be directly collected in the 
CRF but will be captured retrospectively in supportive documentation:  
▪ Stroke (CT or MRI confirmed hemorrhagic or ischemic 
▪ AKI as defined by AKIN criteria 
• New arrhythmias as diagnosed by in the EMR 
• Need for mechanical circulatory support (LVAD, ECMO, Intra-aortic Balloon Pump, 
Impella) 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 15 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
4 Subject Selection Enrollment and Withdrawal 
4.1 
Inclusion Criteria 
 
• Patients/LAR will be consented prior to going to the operating room or in the intensive 
care unit after surgery. 
• The benefits and risks will be discussed. 
 
 Table 1  
Inclusion 
1. Any patient for whom we are able to obtain consent prior to their procedure or 
after their procedure in the intensive care unit. 
2. Patient must have a PA catheter, or a CCO/Flo Trak for the procedure  
3. Is presenting for a procedure in which CPB will be required  
4. Is considered high risk for VS 
a. Patient considered to be at high risk for the development of VS will be 
identified per the guidelines developed by Levin et al11. This includes 
any patient: 
I. 
With pre-CPB vasopressor requirement(s)  
or 
II. 
On pre-operative ACE, or beta-blocker or calcium channel 
blocker therapy  
or 
III. 
With a euroSCORE>6  
or 
IV. 
Presenting for pericardiectomy, aneurysm surgery, LVAD 
surgery or heart transplant, CABG or valve surgery other than a 
single mitral valve repair. 
5. Has no contraindications to arterial line or PA catheter placement 
 
6. Patient must fall into the defined parameters below for the majority of 
measurements over a 30 minute period (ex: 3 out of 5 measurements or 6 of 10, 
etc).  
a. Develops high-dose vasopressors for 30 min or longer and refractory 
hypotension consistent with VS within 24 hours of coming off CPB. 
b. “high-dose vasopressor” will be defined as: 
I. 
Norepinephrine infusion≥0.1mcg/kg/min and/or 
II. 
Dopamine infusion≥ 15mcg/kg/min  
and/or 
III. 
Epinephrine infusion≥0.1mcg/kg/min 
Or 
c. Norepinephrine equivalent infusion of ≥ 0.1mcg/kg/min (Table 1 
Appendix)  
d. “Hypotension consistent with VS” will be defined as: 
I. 
MAP<75 mmHg via arterial line monitor  
7. Cardiac index>2.3L/min/m2 via PA catheter monitor.  
8. If at the time study drug arrives, the patient who previously met criteria has 
fallen out, they must once again meet requirements only one time before the 
drug is given.  
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 16 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
4.2 
Exclusion Criteria 
 
• Age<18 years 
• Known pregnancy or patients without a documented pregnancy test if not menopausal. 
• Known prior anaphylactic or allergic reaction to B12a 
• CKD stage 4 or worse (GFR < 30 ml/min) before study drug administration 
• ECMO (extracorporeal membrane oxygenation) or IABP (intra-aortic balloon pump)prior 
to study consent and post cardiopulmonary bypass 
• Patients currently on cardiopulmonary bypass 
• Circumstances for which the safety of the patient could be jeopardized by continued 
adherence to the study protocol 
4.3 
Subject Recruitment, Enrollment and Screening 
 
Study coordinators will screen all adult (age > 18) patients who are scheduled to undergo 
coronary artery bypass graft surgery with or without valve repair/replacement, complex cardiac 
valve surgery, pericardial resection, and/or ascending aortic surgery at Mayo Clinic 
Rochester.  Eligible patients will be approached by a study coordinator for consent before their 
elective surgical procedure or patient/LAR will be approached after the surgical procedure in the 
intensive care unit if the patient is close to qualifying for the study. After confirming the 
patient’s inclusion and exclusion criteria, the study coordinator at the institution will obtain 
informed consent and assign a study ID number to the study participant.  Screening logs will be 
maintained to allow generation of a CONSORT diagram. 
 
4.4 
Early Withdrawal of Subjects 
• 
We expect early withdrawals to be rare given it is a single intervention.  
• 
Patients will be free to withdraw consent at any time during the study period. 
• 
Patients who withdraw will be included in intention to treat analysis and safety assessment 
and analysis. 
4.4.1 When and How to Withdraw Subjects 
. 
 
• Patient/LAR will be able to withdraw consent at any time if the patient no longer wishes 
to participate.  
 
5 Study Drug  
5.1 
Description 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 17 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
• The study drug, hydroxocobalamin is marketed as Cyanokit® and comes in a 200ml glass 
vial as a red powder which is reconstituted in 200ml of normal saline giving a dark red 
solution.  
5.2 
Treatment Regimen 
 
• 
5g, IV, over 15 min as a single dose. Can order unblinded dose of Cyanokit® within the 
first 4 hours at the discretion of the primary care team. 
5.3 
Method for Assigning Subjects to Treatment Groups 
 
• Patients will be randomized by research pharmacy if they meet inclusion criteria.  
5.4 
Preparation and Administration of Study Drug 
 
• Both the study drug and placebo will be randomized by the research pharmacy. 
5.5 
Subject Compliance Monitoring 
 
• 
Patient non-compliance is not expected to occur as the patient will be intubated and 
ventilated and it is a single dose IV medication administered by OR and ICU staff. 
5.6 
Prior and Concomitant Therapy 
5.7 
Packaging 
 
• A full one time dose will be administered and so no drug return is expected.   
• Drug will be documented by the RN, CRNA or anesthesiologist of record. 
5.7.1 Return or Destruction of Study Drug 
• As per current Mayo practice. 
 
 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 18 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
 
6 Study Procedures 
 
Patient randomized to B12a or placebo.  Data will be measured prospectively for the first 30 
minutes and then taken from the EMR after that. All tests besides vitamin B12 assay and heavy 
metal quant will be done as standard of care and data will only be collected if done as standard of 
care. Vitamin B12 assay and heavy metal quant will be collected at 24 hours (+ 1 hour) and 72 
hours (+ 1 hour) after drug administration.  
 
 
Study Activity 
Day 0 
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Day 7 
30 Day 
F/U 
Study Drug 
X 
X 
(window -
1, -0) 
 
 
 
 
 
 
 
Informed consent 
X 
X 
 
 
 
 
 
 
 
History 
X 
X 
 
 
 
 
 
 
 
Concurrent meds 
X 
X 
 
 
 
 
 
 
 
Physical exam (Ht, 
Wt, VS) 
X 
X 
 
 
 
 
 
 
 
Patient monitoring 
for inclusion 
i
i
X 
X 
 
 
 
 
 
 
 
Randomization  
Res Pharm 
X 
X 
 
 
 
 
 
 
 
CBC w/diff, plts 
X 
X 
X 
X 
X 
X 
X 
X 
 
Serum chemistry a 
X 
X 
X 
X 
X 
X 
X 
X 
 
INR/PTT/Fib/Plt 
X 
X 
X 
X 
X 
X 
X 
X 
 
ABG/Lactateb 
X 
X 
X 
X 
X 
X 
X 
X 
 
Vitamin B12 
Assayc 
 
X 
X 
X 
X 
 
 
 
 
Heavy Metal 
Quantc 
 
X 
X 
X 
X 
 
 
 
 
Hemodynamic 
monitoring 
 
 
 
 
 
 
 
 
 
Patient Call for 
follow up on 
adverse events 
and mortality 
 
 
 
 
 
 
 
 
X 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 19 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
 a: Albumin, alkaline phosphatase, total bilirubin, BUN, calcium, chloride, glucose, LDH, phosphorus, potassium, total  protein,
SGOT [AST], SGPT [13], sodium, creatinine 
 b: PaO2, PaCO2, pH, bicarb, SpO2, lactate, base deficit 
 c: Vitamin B12 assay, heavy metal quant to be collected at 24 hour (+ 1 hour)  and 72 hour (+ 1 hour) after study drug 
administration 
. 
 
7 Statistical Plan 
7.1 
Sample Size Determination 
 
Sample size 
 
Power analysis using the results of our retrospective review revealed a study population of 50 
patients randomized to either B12a or control would detect a mean arterial pressure (MAP) 
increase of 7.3mmHg with a power of 0.8 and a p value of 0.05.   The expected event rate 
triggering randomization is between 10% and 20% based on both historical data from previous 
series and evaluation of the percentage of patients meeting inclusion criteria based on a random 
selection of patients after cardiac surgery at our institution [5, 14].  This will require consent of 
1000 to 2000 patients in order to randomize 50 patients.  Our institution performs approximately 
3000 cardiac surgical cases requiring CPB per year meaning we would need to consent between 
4% and 8% of our cardiac surgical volume over a 2 year study period.    
 
Problems and Limitations         
                                                                                                                                              
Several potential limitations exist with this study.  Firstly there is still no universally accepted 
definition of VS in the literature.  Therefore physiological variables chosen for inclusion will by 
necessity be arbitrary.  We chose variables based on definitions used in previous reviews.  
Furthermore, previous work suggests NOS inhibitors may be most effective early in the disease 
process and may be less effective after prolonged refractory VS [5, 22]. Given this we decided 
intervention with the study drug should occur while vasoplegia is refractory but before 
intervention would be considered as a rescue and therefore infusion of norepinephrine 
equivalents of 0.1mcg/kg/min2 for 30 min was considered appropriate.  
 
7.2 
Statistical Methods 
 
Descriptive Statistics 
 
The primary outcome is change in MAP from baseline over the first 4 hours postoperatively at 
15 min increments post randomization.  Randomized groups will be compared using analysis of 
covariance (ANCOVA), adjusting for baseline MAP prior to randomization.  A p-value <0.05 is 
considered statistically significant. 
 
Secondary outcomes will be compared by treatment arms without adjustment for multiple 
comparisons.  Change in rates of vasopressor and inotropic infusions will be compared by 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 20 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
ANCOVA where the outcome is defined as the infusion rate at 30 minute intervals for the first 4 
hours post B12a administration and models adjust for the baseline value.  Change in systolic 
blood pressure will be analyzed similarly.  Length of stay and ventilator time outcomes will be 
compared by Wilcoxon rank-sum tests; mortality and binary outcomes will be compared between 
randomized arms with a Pearson chi-square or Fisher’s exact test when appropriate. 
As a tertiary aim and exploratory analysis, longitudinally collected data such as daily SOFA 
score will be modeled in a repeated measures analysis.  Treatment groups will be compared by 
assessing whether B12 treatment affects the slope of or change in SOFA scores over time. 
 
Handling of Missing Data 
 
Missing data is expected to be rare as these outcomes are routinely collected in the electronic 
medical record.  The primary analysis will consider complete cases.  Two sensitivity analyses 
may be performed, including multiple imputation of missing data under the missing at random 
mechanism and an analysis under the not missing at random mechanism.  For the latter, methods 
may include shared parameter models or worst-case imputation when the cause of the missing 
data is early mortality 
 
 
Primary Hypothesis:  
 
The use of an intravenous infusion of vitamin B12a in patients with post-cardiotomy vasoplegic 
syndrome receiving high dose vasopressors will result in a statistically significant increase in 
mean arterial blood pressure compared to placebo over the first 4 hours after administration. 
 
 
Secondary Hypothesis:  
 
The use of an intravenous infusion of vitamin B12a in patients with post-cardiotomy vasoplegic 
syndrome will have a statistically significant decrease in vasopressor requirement over the first 4 
hours after administration.  
 
7.3 
Subject Population(s) for Analysis 
 
• All-randomized population:  Any subject randomized into the study, regardless of whether 
they received study drug.  Inclusion and exclusion criteria are provided in table 1.  
• All-treated population:  Any subject randomized into the study that received at least one 
dose of study drug 
• All-completed population:  Only subjects who completed ALL study related procedures 
and follow-up will be included  
 
 
8 Safety and Adverse Events 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 21 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
Unanticipated Problems Involving Risk to Subjects or Others (UPIRTSO) 
Any unanticipated problem or adverse event that meets the following three criteria:  
• Serious: Serious problems or events that results in significant harm, (which may be 
physical, psychological, financial, social, economic, or legal) or increased risk for the 
subject or others (including individuals who are not research subjects). These include: (1) 
death; (2) life threatening adverse experience; (3) hospitalization - inpatient, new, or 
prolonged; (4) disability/incapacity - persistent or significant; (5) birth defect/anomaly; (6) 
breach of confidentiality and (7) other problems, events, or new information (i.e. 
publications, DSMB reports, interim findings, product labeling change) that in the opinion 
of the local investigator may adversely affect the rights, safety, or welfare of the subjects 
or others, or substantially compromise the research data, AND 
• Unanticipated: (i.e. unexpected) problems or events are those that are not already 
described as potential risks in the protocol, consent document, not listed in the 
Investigator’s Brochure, or not part of an underlying disease. A problem or event is 
"unanticipated" when it was unforeseeable at the time of its occurrence. A problem or 
event is "unanticipated" when it occurs at an increased frequency or at an increased 
severity than expected. 
• Related: A problem or event is "related" if it is possibly related to the research procedures. 
 
 
Adverse Event 
An untoward or undesirable experience associated with the use of a medical product (i.e. drug, 
device, biologic) in a patient or research subject. 
Patients undergoing cardiac surgery with CPB sustain a multitude of adverse events as a result of 
their medical condition and the exposure to surgical procedure and CPB.  Therefore, in order to 
make the safety evaluation of vitamin B12a meaningful, only selected adverse events that are 
medically important and/or may have a causal relationship to vitamin B12a will be 
collected.              
 
Serious Adverse Event 
Adverse events are classified as serious or non-serious.  Serious problems/events can be well 
defined and include; 
• death 
• life threatening adverse experience 
• hospitalization 
• inpatient, new, or prolonged; disability/incapacity 
• persistent or significant disability or incapacity 
• birth defect/anomaly 
 
and/or per protocol may be problems/events that in the opinion of the sponsor-investigator 
may have adversely affected the rights, safety, or welfare of the subjects or others, or 
substantially compromised the research data. 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 22 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
All adverse events that do not meet any of the criteria for serious, should be regarded as non-
serious adverse events.  
 
Adverse Event Reporting Period 
 
We will monitor for all adverse events over the first 12 hours after the administration of study 
drug and monitor for acute kidney injury (AKI) and stroke for 72 hours after drug administration. 
Patients will continue to be monitored per standard ICU protocol after this point.  
 
Preexisting Condition 
A preexisting condition is one that is present at the start of the study.  A preexisting condition 
should be recorded as an adverse event if the frequency, intensity, or the character of the 
condition worsens during the study period. 
 
 
General Physical Examination Findings 
At screening, any clinically significant abnormality should be recorded as a preexisting 
condition.  At the end of the study, any new clinically significant findings/abnormalities that 
meet the definition of an adverse event will also be recorded and documented as an adverse 
event.  
 
Post-study Adverse Event 
All unresolved adverse events should be followed by the sponsor-investigator until the events are 
resolved, the subject is lost to follow-up, or the adverse event is otherwise explained.   
 
Hospitalization, Prolonged Hospitalization or Surgery 
Any adverse event that results in hospitalization or prolonged hospitalization aside from the 
anticipated post-surgical hospitalization should be documented and reported as a serious adverse 
event unless specifically instructed otherwise in this protocol.  Any condition responsible for 
surgery should be documented as an adverse event if the condition meets the criteria for an 
adverse event.  
 
Neither the condition, hospitalization, prolonged hospitalization, nor surgery are reported as an 
adverse event in the following circumstances: 
• Hospitalization or prolonged hospitalization for diagnostic or elective surgical procedures 
for a preexisting condition.  Surgery should not be reported as an outcome of an adverse 
event if the purpose of the surgery was elective or diagnostic and the outcome was 
uneventful. 
• Hospitalization or prolonged hospitalization for therapy of the target disease of the study, 
unless it is a worsening or increase in frequency of hospital admissions as judged by the 
clinical investigator. 
 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 23 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
8.1 
Recording of Adverse Events 
Information on all adverse events should be recorded immediately in the source document, and 
also in the appropriate adverse event section of the case report form (CRF). All clearly related 
signs, symptoms, and abnormal diagnostic, laboratory or procedure results should recorded in the 
source document. 
 
All adverse events occurring during the study reporting period must be recorded.  The clinical 
course of each event should be followed until resolution, stabilization, or until it has been 
ultimately determined that the study treatment or participation is not the probable cause.  Serious 
adverse events that are still ongoing at the end of the study period must be followed up, to 
determine the final outcome.  Any serious adverse event that occurs during the Adverse Event 
Reporting Period and is considered to be at least possibly related to the study treatment or study 
participation should be recorded and reported immediately. 
 
8.2 
Reporting of Serious Adverse Events and Unanticipated Problems 
 
When an adverse event has been identified, the study team will take appropriated action 
necessary to protect the study participant and then complete the Study Adverse Event Worksheet 
and log.  The sponsor-investigator will evaluate the event and determine the necessary follow-up 
and reporting required. 
 
8.2.1 Sponsor-Investigator reporting: notifying the Mayo IRB 
 
 
Monitoring activities will be performed by the PI and study team. The investigators will allocate 
adequate time for monitoring activities.  The Investigators will also ensure that the monitor or 
other compliance or quality assurance reviewer is given access to all the study-related documents 
and study related facilities (e.g. pharmacy, diagnostic laboratory, etc.), and has adequate space to 
conduct the monitoring visit. A data safety monitoring board is not required by this institution. 
 
 
The sponsor-investigator will report to the Mayo IRB any UPIRTSOs and Non-UPIRTSOs 
according to the Mayo IRB Policy and Procedures and it will include the following: 
. 
 
• Subject’s name:  
• Medical record number:  
• Disease/histology (if applicable):  
• The date the adverse event occurred:  
• Description of the adverse event:  
• Relationship of the adverse event to the research (drug, procedure, or intervention*):  
• If the adverse event was expected:  
• The severity of the adverse event: (use a table to define severity scale 1-5**) 
• If any intervention was necessary:  

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 24 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
• Resolution: (was the incident resolved spontaneously, or after discontinuing treatment) 
• Date of Resolution:  
 
The sponsor-investigator will review all adverse event reports to determine if specific reports 
need to be made to the IRB and FDA.  The sponsor-investigator will sign and date the adverse 
event report when it is reviewed.  For this protocol, only directly related SAEs/UPIRTSOs will 
be reported to the IRB. 
 
* Relationship Index Example 
 
The relationship of an AE to the Investigational Drug is a clinical decision by the sponsor-
investigator (PI) based on all available information at the time of the completion of the CRF and 
is graded as follows: 
 
1. Not related: a reaction for which sufficient information exists to indicate that the etiology is 
unrelated to the study drug; the subject did not receive the study medication or the temporal 
sequence of the AE onset relative to administration of the study medication is not reasonable or 
the event is c1early related to other factors such as the subject's clinical state, therapeutic 
intervention or concomitant therapy. 
 
2. Unlikely: a clinical event, including laboratory test abnormality, with a temporal relationship 
to drug administration which makes a causal relationship improbable and in which other drugs, 
chemicals, or underlying disease provide plausible explanations. 
 
3. Possible: a clinical event, including laboratory test abnormality, with a reasonable time 
sequence to administration of the drug but which could also be explained by concurrent disease 
or other drugs or chemicals; information on drug withdrawals may be lacking are unclear. 
 
4. Probable: a clinical event including laboratory test abnormality, with a reasonable time 
sequence to administration of the drug, unlikely to be attributed to concurrent disease or other 
drugs or chemicals and which follows a clinically reasonable response on withdrawal (de-
challenge): re-challenge information is not required to fulfi1 this definition. 
 
5. Definite: a reaction that follows a reasonable temporal sequence from administration of the 
drug, or in which the drug level has been established in body fluids or tissues, that follows a 
known or expected response pattern to the suspected drug, and that is confirmed by improvement 
on stopping or reducing the dosage of the drug, and reappearance of the reaction on repeated 
exposure (re-challenge). 
 
** Severity Index Example 
The maximum intensity of an AE during a day should be graded according to the definitions 
below and recorded in details as indicated on the CRF. If the intensity of an AE changes over a 
number of days, then separate entries should be made having distinct onset dates.  
 
1. Mild: AEs are usually transient, requiring no special treatment, and do not interfere with 
patient’s daily activities. 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 25 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
 
2. Moderate: AEs typically introduce a low level of inconvenience or concern to the patient and 
may interfere with daily activities, but are usually ameliorated by simple therapeutic measures. 
 
3. Severe: AEs interrupt a patient's usual daily activity and traditionally require systemic drug 
therapy or other treatment. 
 
8.3 
Unmasking/Unblinding Procedures 
 
Masking and blinding will be carried out by the research pharmacy with unmasking to be 
performed at study completion through the research pharmacy and statistician.  
8.4 
Stopping Rules  
 
In the case of anaphylaxis drug infusion will be stopped. In the event of blood pressure overshoot 
the Vasopressors will be titrated to stay under the upper limit blood pressure goal of the 
treatment team.  Urine and skin discoloration is an expected side effect, there will be no change 
in protocol or management if this occurs. 
 
The study drug has been used safely over a prolonged period with very few reported adverse 
events. We do not expect any other related adverse events. 
 
8.5 
Medical Monitoring 
It is the responsibility of the Principal Investigator to oversee the safety of the study at his/her 
site.  This safety monitoring will include careful assessment and appropriate reporting of adverse 
events as noted above, as well as the construction and implementation of a site data and safety-
monitoring plan (see section 10  “Study Monitoring, Auditing, and Inspecting”).  Medical 
monitoring will include a regular assessment of the number and type of serious adverse events. 
 
8.5.1 Internal Data and Safety Monitoring Board 
 
8.5.2 Independent Data and Safety Monitoring Board 
 
9 Data Handling and Record Keeping 
9.1 
Confidentiality 
Information about study subjects will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  
Those regulations require a signed subject authorization informing the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study 
• Who will have access to that information and why 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 26 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
• Who will use or disclose that information 
• The rights of a research subject to revoke their authorization for use of their PHI.  
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability to use all information collected prior to the revocation of subject 
authorization.  For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect at least vital status (long term survival status that 
the subject is alive) at the end of their scheduled study period. 
9.2 
Source Documents 
Source data is all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source 
data are contained in source documents.  Examples of these original documents, and data records 
include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copies or transcriptions certified after verification as being accurate and complete, 
microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and 
records kept at the pharmacy, at the laboratories, and at medico-technical departments involved 
in the clinical trial. 
9.3 
Case Report Forms 
 
Data Management 
 
Data will be stored in a secure server accessed only by the PI and other study personnel as 
designated by the PI 
 
Data Processing 
 
Data will be collected by the study coordinator and will be entered into REDCap data base which 
is located on a secure drive and accessed only by the PI and other study personnel as designated 
by the PI. 
Retrospective data captured in spreadsheet and kept in secure server  
 
Data Security and Confidentiality 
 
As above 
 
 
Data Clarification Process 
 
9.4 
Records Retention 
 
The sponsor-investigator will maintain records and essential documents related to the conduct of 
the study.  These will include subject case histories and regulatory documents. 
 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 27 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
The sponsor-investigator will retain the specified records and reports for; 
1. Up to 2 years after the marketing application is approved for the drug; or, if a marketing 
application is not submitted or approved for the drug, until 2 years after shipment and 
delivery of the drug for investigational use is discontinued and the FDA has been so 
notified. OR 
2. As outlined in the Mayo Clinic Research Policy Manual –“Retention of and Access to 
Research Data Policy” http://mayocontent.mayo.edu/research-policy/MSS_669717   
whichever is longer 
 
10 Study Monitoring, Auditing, and Inspecting 
10.1 Study Monitoring Plan 
 
The investigator will allocate adequate time for such monitoring activities.  The Investigator will 
also ensure that the monitor or other compliance or quality assurance reviewer is given access to 
all the study-related documents and study related facilities (e.g. pharmacy, diagnostic laboratory, 
etc.), and has adequate space to conduct the monitoring visit. 
 
 
10.2 Auditing and Inspecting 
The investigator will permit study-related monitoring, audits, and inspections by the IRB, the 
sponsor, and government regulatory agencies, of all study related documents (e.g. source 
documents, regulatory documents, data collection instruments, study data etc.).  The investigator 
will ensure the capability for inspections of applicable study-related facilities (e.g. pharmacy, 
diagnostic laboratory, etc.). 
 
Participation as an investigator in this study implies acceptance of potential inspection by 
government regulatory authorities and applicable compliance offices. 
11 Ethical Considerations 
This study is to be conducted according to United States government regulations and 
Institutional research policies and procedures. 
 
This protocol and any amendments will be submitted to a properly constituted local Institutional 
Review Board (IRB), in agreement with local legal prescriptions, for formal approval of the 
study.  The decision of the IRB concerning the conduct of the study will be made in writing to 
the sponsor-investigator before commencement of this study. 
 
All subjects/LAR for this study will be provided a consent form describing this study and 
providing sufficient information for subjects to make an informed decision about their 
participation in this study.  This consent form will be submitted with the protocol for review and 
approval by the IRB for the study.  The formal consent of a subject, using the Approved IRB 
consent form, must be obtained before that subject undergoes any study procedure.  The consent 
form must be signed by the subject/LAR, and the individual obtaining the informed consent. 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 28 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
 
12 Study Finances 
12.1 Funding Source 
 
We are hopeful of receiving a grant through the Society of Cardiovascular Anesthesiologists as 
well as study drug through Pfizer.  
12.2 Conflict of Interest 
 
No conflict of interest declared by study personnel 
13 Publication Plan 
 
The study will be linked to ClinicalTrials.gov prior to subject recruitment and enrollment, as well 
as posting of results to ClinicalTrials.gov within 12 months of final data collection for the 
primary outcome.  
 
Link to protocol registration site for ClinicalTrials.gov:  https://register.clinicaltrials.gov/ 
 
 
14 Protocol Addendum 
 
Although B12 has an excellent safety profile, to date no study has evaluated serum levels of B12 and cobalt after 
dosing in this patient population. Recently, a reviewer on a grant application recommended adding a couple labs to 
the research study since the vitamin b12 contains the heavy metal cobalt.  A decision was made by the investigator 
and the study team to collect labs up to 16 patients who receive study drug. The labs that will be collected are the 
vitamin b12 assay and heavy metal quant at 24 hours and 72 hours post drug administration. The study will be paying 
for these lab tests so the patient should not see any billing for them.  
Obtaining these lab results will help to develop a pharmacokinetic profile in patients receiving the drug and it would 
help us understand the effects of Vitamin B12 in this study population.  
 
15 References 
 
 
1. 
Fischer, G.W. and M.A. Levin, Vasoplegia during cardiac surgery: current concepts and 
management. Semin Thorac Cardiovasc Surg, 2010. 22(2): p. 140-4. 
2. 
Roderique, J.D., et al., The use of high-dose hydroxocobalamin for vasoplegic syndrome. Ann 
Thorac Surg, 2014. 97(5): p. 1785-6. 
3. 
Oz, M., et al., Cellular and molecular actions of Methylene Blue in the nervous system. Med Res 
Rev, 2011. 31(1): p. 93-117. 
4. 
Lenglet, S., F. Mach, and F. Montecucco, Methylene blue: potential use of an antique molecule in 
vasoplegic syndrome during cardiac surgery. Expert Rev Cardiovasc Ther, 2011. 9(12): p. 1519-
25. 
5. 
Levin, R.L., et al., Methylene blue reduces mortality and morbidity in vasoplegic patients after 
cardiac surgery. Ann Thorac Surg, 2004. 77(2): p. 496-9. 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 29 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
6. 
Gomes, W.J., et al., Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino), 
1998. 39(5): p. 619-23. 
7. 
Dasta, J.F., et al., Daily cost of an intensive care unit day: the contribution of mechanical 
ventilation. Crit Care Med, 2005. 33(6): p. 1266-71. 
8. 
Halpern, N.A. and S.M. Pastores, Critical Care Medicine Beds, Use, Occupancy, and Costs in the 
United States: A Methodological Review. Crit Care Med, 2015. 43(11): p. 2452-9. 
9. 
Gershengorn, H.B., A. Garland, and M.N. Gong, Patterns of Daily Costs Differ for Medical and 
Surgical Intensive Care Unit Patients. Ann Am Thorac Soc, 2015. 12(12): p. 1831-6. 
10. 
Gerth, K., et al., Nitric oxide scavenging by hydroxocobalamin may account for its hemodynamic 
profile. Clin Toxicol (Phila), 2006. 44 Suppl 1: p. 29-36. 
11. 
Weinberg, J.B., et al., Inhibition of nitric oxide synthase by cobalamins and cobinamides. Free 
Radic Biol Med, 2009. 46(12): p. 1626-32. 
12. 
Woehlck, H.J., et al., Hydroxocobalamin for Vasoplegic Syndrome in Liver Transplantation: 
Restoration of Blood Pressure Without Vasospasm. A A Case Rep, 2016. 7(12): p. 247-250. 
13. 
Khanna, A., et al., Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med, 2017. 
377(5): p. 419-430. 
14. 
Omar, S., A. Zedan, and K. Nugent, Cardiac vasoplegia syndrome: pathophysiology, risk factors 
and treatment. Am J Med Sci, 2015. 349(1): p. 80-8. 
15. 
Evora, P.R., et al., Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene 
blue revised. Rev Bras Cir Cardiovasc, 2015. 30(1): p. 84-92. 
16. 
Loscalzo, J. and G. Welch, Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc 
Dis, 1995. 38(2): p. 87-104. 
17. 
Kofidis, T., et al., Reversal of severe vasoplegia with single-dose methylene blue after heart 
transplantation. J Thorac Cardiovasc Surg, 2001. 122(4): p. 823-4. 
18. 
Evora, P.R., P.J. Ribeiro, and J.C. de Andrade, Methylene blue administration in SIRS after 
cardiac operations. Ann Thorac Surg, 1997. 63(4): p. 1212-3. 
19. 
Leyh, R.G., et al., Methylene blue: the drug of choice for catecholamine-refractory vasoplegia 
after cardiopulmonary bypass? J Thorac Cardiovasc Surg, 2003. 125(6): p. 1426-31. 
20. 
Evora, P.R. and R.L. Levin, Methylene blue as drug of choice for catecholamine-refractory 
vasoplegia after cardiopulmonary bypass. J Thorac Cardiovasc Surg, 2004. 127(3): p. 895-6; 
author reply 896. 
21. 
Ozal, E., et al., Preoperative methylene blue administration in patients at high risk for vasoplegic 
syndrome during cardiac surgery. Ann Thorac Surg, 2005. 79(5): p. 1615-9. 
22. 
Fernandes, D., et al., Nitric oxide-dependent reduction in soluble guanylate cyclase functionality 
accounts for early lipopolysaccharide-induced changes in vascular reactivity. Mol Pharmacol, 
2006. 69(3): p. 983-90. 
23. 
Weiner, M.M., et al., Methylene blue is associated with poor outcomes in vasoplegic shock. J 
Cardiothorac Vasc Anesth, 2013. 27(6): p. 1233-8. 
24. 
Evora, P.R. and A.J. Rodrigues, Methylene blue revised. J Thorac Cardiovasc Surg, 2006. 
131(1): p. 250-1; author reply 251. 
25. 
Andritsos, M.J., Con: methylene blue should not be used routinely for vasoplegia perioperatively. 
J Cardiothorac Vasc Anesth, 2011. 25(4): p. 739-43. 
26. 
Ng, B.K. and A.J. Cameron, The role of methylene blue in serotonin syndrome: a systematic 
review. Psychosomatics, 2010. 51(3): p. 194-200. 
27. 
Sills, M.R. and W.H. Zinkham, Methylene blue-induced Heinz body hemolytic anemia. Arch 
Pediatr Adolesc Med, 1994. 148(3): p. 306-10. 
28. 
DesLauriers, C.A., A.M. Burda, and M. Wahl, Hydroxocobalamin as a cyanide antidote. Am J 
Ther, 2006. 13(2): p. 161-5. 
29. 
Cai, Y., et al., The use of intravenous hydroxocobalamin as a rescue in methylene blue-resistant 
vasoplegic syndrome in cardiac surgery. Ann Card Anaesth, 2017. 20(4): p. 462-464. 
30. 
Petrikovics, I., et al., Past, present and future of cyanide antagonism research: From the early 
remedies to the current therapies. World J Methodol, 2015. 5(2): p. 88-100. 
31. 
Shah, P.R., et al., Hydroxocobalamin for the treatment of cardiac surgery-associated vasoplegia: 
a case series. Can J Anaesth, 2017. 
32. 
Cheungpasitporn, W., et al., High-dose hydroxocobalamin for vasoplegic syndrome causing false 
blood leak alarm. Clin Kidney J, 2017. 10(3): p. 357-362. 

Vitamin B12a Vasoplegic Syndrome 
 
Version9.0 
 
 
Revised 3Nov2021 
Page 30 of 30 
Dr. James Nelson 
 
CONFIDENTIAL 
 
16 Attachments 
Appendix  
Table 1. (from ATHOS 3 trial) Angiotensin II for the Treatment of Vasodilatory Shock N 
Engl J Med 2017; 377:419-430  
 
 
 
 
 
Drug 
Dose 
Norepinephrine  
equivalent  
Epinephrine 
0.1 mcg/kg/min 
0.1 mcg/kg/min 
Norepinephrine 
0.1 mcg/kg/min 
0.1 mcg/kg/min 
Dopamine 
15 mcg/kg/min 
0.1 mcg/kg/min 
Vasopressin 
0.04U/min 
0.05 mcg/kg/min